SOUTH SAN FRANCISCO, Calif. — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced new data presentations highlighting the broad potential of its BBB-crossing enzyme replacement...
Latest News
DAKAR, Senegal — World-famous singer Youssou Ndour has a voice that is recognized across the globe. Now he’s using that voice to amplify the fight against malaria in his home country of Senegal with a new song “Xeex Sibbiru” (“Fight Malaria” in Wolof) and a multi-year partnership with Malaria No...
ST. PAUL, Minn. – People with memory problems who are depressed are more likely to develop Alzheimer’s disease compared to people who are not depressed, according to a study published in the June 16, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology. However, the...
MINNEAPOLIS – In some diseases, the underlying processes can start years before a diagnosis is made. A new study finds that people who later develop multiple sclerosis (MS) are more likely to have conditions like depression, constipation and urinary tract infections five years before their MS diagnosis than people who...
TAMPA, Fla. — Pancreatic cancer presents a challenging prognosis, marked by a five-year overall survival rate of merely 12.5%. Diagnosis frequently occurs at an advanced stage, characterized by metastasis to distant sites. The intricate molecular mechanisms governing pancreatic cancer metastasis remain a subject of ongoing research and exploration. In a recent...
SAN DIEGO, CA – Dermata Therapeutics, Inc., a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the issuance of a new patent in Japan for its DMT410 program for the treatment of hyperhidrosis. The patent, entitled “Compositions for the treatment of skin conditions,” (Japanese...
Sitting in his favorite tiny red wooden chair, Teddy Christiansen peers out the window, smiling as he watches his older sister, Raelyn, play in the front yard. Before long, Teddy springs from the chair, itching to go outside himself. The bespectacled 33-month-old is everything he should be at his age:...
CARLSBAD, Calif. — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced favorable data from a Phase 1 single- and multiple-ascending dose (SAD/MAD) trial of DT-168 in healthy volunteers, which will be presented on May 2, 2025 at Eyecelerator @ Park...
TOKYO, Japan & BASKING RIDGE, N.J. — The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy in patients with HER2 expressing (IHC 3+/2+/1+) advanced high-grade epithelial ovarian cancer...
Gainesville, Florida – Scientists have developed a saliva test that screens for breast cancer, which is showing promising results in experimental testing, according to a study published Tuesday. The new hand-held device detects breast cancer biomarkers from a tiny sample of spit, say researchers from the University of Florida and...